The Daikyo Crystal Zenith Insert Needle Syringe System - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

The Daikyo Crystal Zenith Insert Needle Syringe System


The Daikyo Crystal Zenith® Insert Needle Syringe System: A first-in-class, prefillable syringe solution for drug administration

Protect your drug product’s integrity with the industry’s first adhesive- and tungsten-free insert needle syringe system – the Daikyo Crystal Zenith Insert Needle Syringe System. Made from a break-resistant cyclic olefin polymer, the insert needle design minimizes potential contamination and product waste due to manufacturing and performance issues associated with traditional glass and staked-needle syringe systems.

The syringe barrel and piston are silicone-oil-free to help maximize purity and reduce risk. The piston with Daikyo Flurotec® barrier film helps minimize the effect of extractables and leachables. Flurotec barrier film also provides superior functional performance without the addition of silicone oil for lubricity. The syringe system is provided sterile and ready-to-fill in a package designed to be compatible with existing filling technologies.

The break-resistant system offers a variety of benefits that maximize value, enhance delivery and minimize risk, including:

  • Designed to maximize stability, purity and efficacy of your drug product
  • Manufactured to exacting standards in a clean room environment
  • 100% vision inspection
  • Potential to reduce protein aggregation caused by packaging materials
  • Excellent glass-like transparency
  • Suitable for high-viscosity products and those requiring low-temperature storage
  • Designed to be compatible with auto-injectors
  • Custom design and molding capabilities provide the flexibility to develop innovative new systems

 

West Pharmaceutical Services, Inc.
Email: westpharmaceuticalservices@westpharma.com
Website: www.westpharma.com

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
70%
Breakthrough designations
4%
Protecting the supply chain
17%
Expedited reviews of drug submissions
2%
More stakeholder involvement
7%
View Results
Eric Langerr Outsourcing Outlook Eric LangerRelationship-building at Top of Mind for Clients
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerRisk Reduction Top Driver for Biopharmaceutical Raw Material Development
Jill Wechsler Regulatory Watch Jill Wechsler Changes and Challenges for Generic Drugs
Faiz Kermaini Industry Insider Faiz KermainiNo Signs of a Slowdown in Mergers
CMOs and the Track-and-Trace Race: Are You Engaged Yet?
Ebola Outbreak Raises Ethical Issues
Better Comms Means a Fitter Future for Pharma, Part 2: Realizing the Benefits of Unified Communications
Better Comms Means a Fitter Future for Pharma, Part 1: Challenges and Changes
Sandoz Wins Biosimilar Filing Race

Click here